Top Executives From Biotrial, A Leading Contract Research Organization (CRO) In The Field Of Early Compound Development, To Speak At 3rd AGAH/Club Phase I Joint Annual Meeting, A Key European Clinical Pharmacology Event
Rennes, France — April 23rd, 2009 This conference organized by the AGAH (Association for Applied Human Pharmacology)/Club Phase I (Association of early compound development professionals) aims to provide an indispensable European forum for scientific experts in the field of pharmacology.
This meeting will address how sponsors, investigators, regulatory authorities and ethics committees are adapting to the new challenges raised by the first administration of a new compound to man. It will bring together over 250 professionals from varied backgrounds, companies and countries. A number of pharmaceutical and biotech senior executives from all over Europe are expecting to attend the event, including specialists from Abbott, Aepodia, Bayer Schering, Boehringer Ingelheim, Evotec, Galderma, GSK, Merck Serono, Nycomed, Sanofi-Aventis, UCB and Wyeth.
More than 15 Biotrial key staff will be attending this event including: Jean-Marc Gandon Biotrial CEO, Alain Patat VP of Medical and Scientific Affairs, and Didier Chassard Associate Medical and Scientific Director. Within the ambitious and unique agenda planned for this conference Biotrial executives will be speaking on various topics such as: “Accreditation of phase I units in France”, “Stopping criteria in first-in-man studies”, “Update on the design of studies of drug-drug interaction with special focus on transporters”.
“As the president of Club Phase I, I am particularly proud and excited that Biotrial is such an active participant to this key conference,” stated Alain Patat, Biotrial’s VP of Medical and Scientific Affairs. “The benefits of such an event last well beyond the two-day conference. It is a place of highly rich intellectual exchange and a time when we can get to know our customers and market better.” Jean-Marc Gandon, Biotrial’s CEO, added: “We are looking forward to participating and attending this important conference, which addresses pertinent topics developed by top European experts in the field of early compound development. It is a great opportunity to learn about recent advances in the field of early clinical research. As a CRO it is also key for Biotrial to understand how our market evolved to continuously adapt to its needs.”
Biotrial will be exhibiting at booth number S5.
About Biotrial
Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial (www.biotrial.com) is an independent and privately owned CRO focusing mainly on early drug discovery and development services. With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners. With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Central Labs (ECG, Imaging), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.
For further information please contact Anne Peron at [+33] (0)2 99 599 191 or visit www.biotrial.com.
About Club Phase I
http://www.clubphase1.fr
Club Phase I is a French association, with all members involved in the field of early compound development (Industry, CRO, Hospitals-Universities). Since 1993, it provides a unique place where professionals can exchange – while keeping confidentiality obligations – scientific, methodological, and regulatory point of views and experiences. About AGAH http://www.agah.info/en.html The Association for Applied Human Pharmacology (AGAH) is a scientific medical non-profit organization which members work in the field of explorative drug development and human pharmacology. The organization is particularly open for professionals who work in the field of translational medicine (i.e. bringing new medicinal products from the bench into clinical research).